Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL
Public ClinicalTrials.gov record NCT04404283. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Participants in this study will have diffuse large B-cell lymphoma (DLBCL) that has come back or not gotten better with treatment. The trial will study whether brentuximab vedotin plus two drugs works better to treat this type of cancer than the two drugs alone. Participants will be randomly assigned to get either brentuximab vedotin or placebo. The placebo will look like brentuximab vedotin, but has no medicine in it. Since the study is "blinded," participants and their doctors will not know whether a participant gets brentuximab vedotin or placebo. All participants in the study will get rituximab and lenalidomide. These are drugs that can be used to treat DLBCL.
Study identification
- NCT ID
- NCT04404283
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 239 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 20, 2020 (Actual)
- Primary completion
- Jan 23, 2026 (Actual)
- Completion
- Dec 31, 2026 (Estimated)
- Last update posted
- Jul 22, 2026
2020 – 2026
United States locations
- U.S. sites
- 47
- U.S. states
- 12
- U.S. cities
- 34
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Central Alabama Research | Birmingham | Alabama | 35209 | — |
| University of California Davis Comprehensive Cancer Center | Sacramento | California | 95817 | — |
| University of California Davis Medical Center | Sacramento | California | 95817 | — |
| Florida Cancer Specialists | Bonita Springs | Florida | 34135 | — |
| Florida Cancer Specialists | Bradenton | Florida | 34211 | — |
| Florida Cancer Specialists | Cape Coral | Florida | 33909 | — |
| Florida Cancer Specialists | Daytona Beach | Florida | 32117 | — |
| Florida Cancer Specialists | Fort Myers | Florida | 33905 | — |
| Florida Cancer Specialists | Fort Myers | Florida | 33908 | — |
| Florida Cancer Specialists | Naples | Florida | 34102 | — |
| Florida Cancer Specialists | Port Charlotte | Florida | 33980 | — |
| Florida Cancer Specialists | Sarasota | Florida | 34232 | — |
| Florida Cancer Specialists | Sarasota | Florida | 34236 | — |
| Florida Cancer Specialists | Stuart | Florida | 34994 | — |
| Florida Cancer Specialists | Venice | Florida | 34285 | — |
| Florida Cancer Specialists | Venice | Florida | 34292 | — |
| Florida Cancer Specialists | Vero Beach | Florida | 32960 | — |
| Florida Cancer Specialists | Wellington | Florida | 33414 | — |
| Florida Cancer Specialists | West Palm Beach | Florida | 33401 | — |
| MidAmerica Division, Inc. c/o Menorah Medical Center | Overland Park | Kansas | 66209 | — |
| University of Maryland, Greenebaum Comprehensive Cancer Center | Baltimore | Maryland | 21201 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Henry Ford Hospital | Detroit | Michigan | 48202 | — |
| Karmanos Cancer Institute Weisberg Cancer Treatment Center | Farmington Hills | Michigan | 48334 | — |
| Henry Ford Medical Center - Columbus | Novi | Michigan | 48377 | — |
| Siteman Cancer Center - St. Peters | City of Saint Peters | Missouri | 63376 | — |
| Siteman Cancer Center - West County | Creve Coeur | Missouri | 63141 | — |
| MidAmerica Division, Inc. c/o Centerpoint Medical Center | Independence | Missouri | 64057 | — |
| MidAmerica Division, Inc., c/o Research Medical Center | Kansas City | Missouri | 64132 | — |
| Barnes Jewish-Hospital | St Louis | Missouri | 63110 | — |
| Washington University School of Medicine - Siteman Cancer Center | St Louis | Missouri | 63110 | — |
| Siteman Cancer Center - South County | St Louis | Missouri | 63129 | — |
| Siteman Cancer Center - North County | St Louis | Missouri | 63136 | — |
| Oncology_Hematology Care Clinical Trials,LLC | Cincinnati | Ohio | 45211 | — |
| University of Cincinnati Medical Center | Cincinnati | Ohio | 45219 | — |
| Oncology_Hematology Care Clinical Trials,LLC | Cincinnati | Ohio | 45236 | — |
| Oncology_Hematology Care Clinical Trials,LLC | Cincinnati | Ohio | 45242 | — |
| Oncology_Hematology Care Clinical Trials,LLC | Cincinnati | Ohio | 45245 | — |
| Oncology_Hematology Care Clinical Trials,LLC | Fairfield | Ohio | 45014 | — |
| West Chester Hospital | West Chester | Ohio | 45069 | — |
| Oncology Associates of Oregon, P.C. | Eugene | Oregon | 97401 | — |
| Roper St. Francis Healthcare | Charleston | South Carolina | 29414 | — |
| Roper St. Francis Healthcare | Mt. Pleasant | South Carolina | 29464 | — |
| Roper St. Francis Healthcare | North Charleston | South Carolina | 29406 | — |
| US Oncology Investigational Products Center | Irving | Texas | 75063 | — |
| University of Virginia Cancer Center. | Charlottesville | Virginia | 22903 | — |
| University of Virginia Health System | Charlottesville | Virginia | 22908 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 96 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04404283, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 22, 2026 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04404283 live on ClinicalTrials.gov.